- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
PAPER OF THE WEEK: In 2002, Researchers Found Early Use of Etanercept Improved Quality of Life In RA
As part of our anniversary celebration, today we launch “Paper of the Week,” which will look back at some of the most influential research articles and commentary that have appeared in The American Journal of Managed Care® over the past 25 years, and why they are important today.
This year, The American Journal of Managed Care® celebrates its 25th anniversary. The print journal is the leading source of peer-reviewed literature on healthcare outcomes, but today, the AJMC® family of publications and multimedia is much more. As part of our anniversary celebration, today we launch “Paper of the Week,” which will look back at some of the most influential research articles and commentary that have appeared in The American Journal of Managed Care® over the past 25 years, and why they are important today.
This week’s paper is from March 2002.
“Health-Related Quality of Life in Early Rheumatoid Arthritis: Impact of Disease and Treatment Response” used 2 different scoring systems to measure both general health status and specific effects of RA, both before and after patients received the biologic etanercept, sold as Enbrel by Amgen.
The authors, led by Mark Kosinski, MA, of QualityMetric, Inc (now part of Optum), showed that starting patients on etanercept early in the progression of RA brought a rapid response in their quality of life.
The paper has been cited more than 200 times, and Enbrel went on to become Amgen’s top-selling product.
Enbrel is so important that Amgen went to court last year and won a major federal patent case to protect Enbrel against biosimilar competitors. AJMC®’s sister site, the Center for Biosimilars®, has covered the patent dispute, and you can learn more from the podcast Not So Different.
To read our Paper of the Week, visit ajmc.com.
And for the October podcast, visit our Center for Biosimilars.
Managed Care Reflections: A Q&A With Hoangmai H. Pham, MD, MPH
April 1st 2025To mark the 30th anniversary of The American Journal of Managed Care® (AJMC®), each issue in 2025 will include a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The April issue features a conversation with Hoangmai H. Pham, MD, MPH, a member of AJMC’s editorial board and the president and CEO of the Institute for Exceptional Care (IEC).
Read More
Managed Care Reflections: A Q&A With Julia Adler-Milstein, PhD
March 4th 2025To mark the 30th anniversary of The American Journal of Managed Care, each issue in 2025 includes reflections from a thought leader on what has changed over the past 3 decades and what’s next for managed care. The March issue, which is our annual health information technology (IT) theme issue, features a conversation with Julia Adler-Milstein, PhD, professor of medicine at the University of California, San Francisco, and guest editor of the 2014 health IT issue.
Read More
How Health Care Institutions Can Leverage Biosimilars to Generate Savings
August 17th 2022On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
Listen
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP
February 20th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes reflections from a thought leader on what has changed over the past 3 decades and what’s next for managed care. The February issue features a retrospective by Richard J. Gilfillan, MD, former director of the Center for Medicare and Medicaid Innovation; and Donald M. Berwick, MD, MPP, former administrator of CMS.
Read More
